Sei Investments Co. Purchases 233,732 Shares of OraSure Technologies, Inc. $OSUR

Sei Investments Co. boosted its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 126.9% in the first quarter, Holdings Channel reports. The fund owned 417,958 shares of the medical instruments supplier’s stock after acquiring an additional 233,732 shares during the period. Sei Investments Co.’s holdings in OraSure Technologies were worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Prudential Financial Inc. acquired a new stake in shares of OraSure Technologies in the second quarter valued at about $31,000. Quadrature Capital Ltd bought a new position in shares of OraSure Technologies in the fourth quarter worth about $28,000. Diversify Wealth Management LLC acquired a new position in shares of OraSure Technologies during the 1st quarter worth about $36,000. Amundi acquired a new position in shares of OraSure Technologies during the 1st quarter worth about $47,000. Finally, BNP Paribas Financial Markets boosted its stake in OraSure Technologies by 102.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 7,720 shares during the period. 93.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on OSUR shares. Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Wall Street Zen upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $3.00.

OraSure Technologies Price Performance

Shares of OSUR stock opened at $3.88 on Wednesday. OraSure Technologies, Inc. has a one year low of $2.08 and a one year high of $4.58. The stock has a fifty day moving average price of $4.16 and a 200 day moving average price of $3.45. The stock has a market cap of $267.13 million, a P/E ratio of -5.62 and a beta of 1.00.

Insider Activity

In other OraSure Technologies news, Director Steven Kyle Boyd acquired 25,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was bought at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director owned 113,462 shares in the company, valued at $339,251.38. This represents a 28.26% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 4.70% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.